Trial Profile
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Oct 2021
Price :
$35
*
At a glance
- Drugs Abaloparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Radius Health Inc.
- 12 Oct 2021 Status changed from active, no longer recruiting to completed.
- 22 Sep 2021 According to a Radius media release, the following sentence was added to the MOA section of the TYMLOS (abaloparatide) label: Once-daily administration of abaloparatide stimulates new bone formation on trabecular and cortical bone surfaces by stimulation of osteoblastic activity. This addition is based on the findings from this study.
- 21 Sep 2020 Planned End Date changed from 30 Jun 2020 to 15 Jul 2021.